| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 1
| Issue : 2 | Page : 106-109 |
|
|
The use of cerebroprotein hydrolysate in dementia: A case series of 25 cases seen in a tertiary general hospital
Mosam Phirke, Avinash Desousa, Nilesh Shah, Sushma Sonavane, Anup Bharati
Department of Psychiatry, Lokmanya Tilak Municipal Medical College, Mumbai, Maharashtra, India
Correspondence Address:
Dr. Avinash Desousa
Carmel, 18, St. Francis Road, Off S. V. Road, Santacruz West, Mumbai - 400 054, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2348-9995.152431
|
|
|
Background: Cerebroprotein hydrolysate (Cerebrolysin) is a pharmacological and neurotrophic agent that has been used widely in the management of various forms of dementia.
Purpose: The present paper presents a retrospective chart review of 25 patients with dementia visiting a tertiary general hospital psychiatry unit who received cerebroprotein hydrolysate as an add on treatment for dementia.
Materials and Methods: Twenty-five patients were administered 20 doses of cerebroprotein hydrolysate intravenously at a dose of 60 mg in 250 ml normal saline over 1-2 h after a test dose on 20 consecutive days. The cognitive assessment was done before the first injection and after the last dose using the Adenbrook's Cognitive Examination-Revised (ACER) and the Mini Mental Status Examination (MMSE).
Results: There was significant improvement in scores on the ACER and MMSE, although the final scores remained in the dementia range. None of the patients experienced any major side effects.
Conclusions: Cerebroprotein thus is a useful pharmacological option in the management of dementia and warrants further study and exploration. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
